drugset
drugset / Trial / NCT05448885

Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma

NCT05448885 ↗

Phase 2 Unknown 50 enrolled Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NaSingle-groupOpen-labelTreatment

Summary

To estimate the efficacy and safety of tislelizumab for stage IVA locally advanced nasopharyngeal carcinoma combined with induction chemotherapy and concurrent chemoradiotherapy, followed by maintenance therapy

Timeline

Start
2021-09-01
Primary completion
2025-09-01
Completion
2025-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Tislelizumab Monoclonal antibody 200 mg —

Indications

nasopharyngeal carcinoma